Format

Send to

Choose Destination
See comment in PubMed Commons below
Mod Rheumatol. 2014 Sep;24(5):855-7. doi: 10.3109/14397595.2013.874740. Epub 2014 Feb 11.

Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus.

Author information

1
Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.

Abstract

High-dose steroids, immunosuppressants such as cyclophosphamide and cyclosporine, and high-dose intravenous immunoglobulin have all been used to control hemophagocytic lymphohistiocytosis (HLH) or autoimmune hemolytic anemia (AIHA) associated with systemic lupus erythematosus (SLE); however, some patients are refractory to treatment. Rituximab has successfully resolved many of the refractory manifestations of SLE. Here, we report a case of HLH and AIHA associated with SLE that was refractory or intolerable to conventional therapy, but was successfully treated with rituximab.

KEYWORDS:

Hemophagocytic lymphohistiocytosis; Refractory; Rituximab; Systemic lupus erythematosus

PMID:
24517558
DOI:
10.3109/14397595.2013.874740
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center